A pharmacologically based multiscale mathematical model of angiogenesis and its use in investigating the efficacy of a new cancer treatment strategy

Journal of Theoretical Biology

Volumn 260, Issue 4, 2009, Pages 545-562

  Billy, Frédérique ^a,b   Ribba, Benjamin ^a,c,d   Saut, Olivier ^e   Morre Trouilhet, Hélène ^a,b   Colin, Thierry ^e   Bresch, Didier ^g   Boissel, Jean Pierre ^a,b   Grenier, Emmanuel ^a,c,f   Flandrois, Jean Pierre ^a,b  

^a UNIVERSITÉ DE LYON   (France)

^b UNIVERSITÉ LYON 1   (France)

^c UNIVERSITÉ DE LYON   (France)

^d UNIVERSITÉ CLAUDE BERNARD LYON 1   (France)

^e UNIVERSITÉ DE BORDEAUX   (France)

^f UNITÉ DE MATHÉMATIQUES PURES ET APPLIQUÉES   (France)

^g UNIVERSITÉ DE SAVOIE   (France)

Author keywords

Angiogenesis; Cell cycle; Multiscale mathematical modeling; Optimization of cancer treatments; Pharmacological law; Tumor growth

Indexed keywords

ENDOSTATIN;

CANCER; DISEASE TREATMENT; DRUG; NUMERICAL MODEL; TUMOR;

ARTICLE; CANCER CELL; CANCER GENE THERAPY; CELL CYCLE; DRUG EFFICACY; ENDOTHELIUM CELL; GENE OVEREXPRESSION; MATHEMATICAL MODEL; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; SIMULATION; TREATMENT DURATION; TUMOR GROWTH; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANGIOPOIETINS; ENDOSTATINS; ENDOTHELIUM, VASCULAR; GENE THERAPY; HUMANS; MODELS, BIOLOGICAL; NEOPLASM PROTEINS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; OXYGEN CONSUMPTION; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 70249113326     PISSN: 00225193     EISSN: 10958541     Source Type: Journal    
DOI: 10.1016/j.jtbi.2009.06.026     Document Type: Article

References (66)

1. Addison-Smith B., McElwain D.L.S., and Maini P.K. A simple mechanistic model of sprout spacing in tumour-associated angiogenesis. J. Theor. Biol. 250 1 (2008) 1-15
2. Ahmad S.A., Liu W., Jung Y.D., Fan F., Reinmuth N., Bucana C.D., and Ellis L.M. Differential expression of angiopoietin-1 and angiopoietin-2 in colon carcinoma. A possible mechanism for the initiation of angiogenesis. Cancer 92 5 (2001) 1138-1143
3. Alarcón T., Byrne H., and Maini P. A multiple scale model for tumor growth. Multiscale Model Simul. 3 (2005) 440-475
4. Anderson A.R.A., and Chaplain M.A.J. Continuous and discrete mathematical models of tumor-induced angiogenesis. Bull. Math. Biol. 60 5 (1998) 857-899
5. Araujo R.P., and McElwain D.L.S. New insights into vascular collapse and growth dynamics in solid tumors. J. Theor. Biol. 228 3 (2004) 335-346
6. Araujo R.P., and McElwain D.L.S. A mixture theory for the genesis of residual stresses in growing tissues I: a general formulation. SIAM J. Appl. Math. 65 (2005) 1261-1284
7. Araujo R.P., and McElwain D.L.S. A mixture theory for the genesis of residual stresses in growing tissues II: solutions to the biphasic equations for a multicell spheroid. SIAM J. Appl. Math. 66 2 (2005) 447-467
8. Araujo R.P., and McElwain D.L.S. The nature of the stresses induced during tissue growth. Appl. Math. Lett. 18 (2005) 1081-1088
9. Araujo R.P., and McElwain D.L.S. The role of mechanical host-tumour interactions in the collapse of tumour blood vessels and tumour growth dynamics. J. Theor. Biol. 238 4 (2006) 817-827
10. Ausprunk D.H., and Folkman J. Migration and proliferation of endothelial cells in preformed and newly formed blood vessels during tumor angiogenesis. Microvasc. Res. 14 1 (1977) 53-65
11. Bartha K., and Rieger H. Vascular network remodeling via vessel cooption, regression and growth in tumors. J. Theor. Biol. 241 4 (2006) 903-918
12. Baxter L.T., and Jain R.K. Transport of fluid and macromolecules in tumors. I. Role of interstitial pressure and convection. Microvasc. Res. 37 1 (1989) 77-104
13. Benjamin L.E., and Keshet E. Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal. Proc. Natl. Acad. Sci. USA 94 16 (1997) 8761-8766
14. Bergers G., and Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer 8 8 (2008) 592-603
15. Blagosklonny M.V., and Pardee A.B. The restriction point of the cell cycle. Cell Cycle 1 2 (2002) 103-110
16. Boucher Y., Baxter L.T., and Jain R.K. Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy. Cancer Res. 50 15 (1990) 4478-4484
17. Bresch, D., Colin, T., Grenier, E., Ribba, B., Saut, O., 2009a. Computational modeling of solid tumor growth: the avascular stage. Submitted.
18. Bresch, D., Colin, T., Grenier, E., Ribba, B., Saut, O., 2009b. A viscoelastic model for avascular tumor growth. Submitted.
19. Byrne H.M., and Chaplain M.A. Growth of necrotic tumors in the presence and absence of inhibitors. Math. Biosci. 135 15 (1996) 187-216
20. Davis S., Aldrich T.H., Jones P.F., Acheson A., Compton D.L., Jain V., Ryan T.E., Bruno J., Radziejewski C., Maisonpierre P.C., and Yancopoulos G.D. Isolation of angiopoietin-1, a ligand for the Tie2 receptor, by secretion-trap expression cloning. Cell 87 7 (1996) 1161-1169
21. DeVita V.T., Hellman S., and Rosenberg S.A. Cancer-Principles and Practice of Oncology. seventh ed (2005), Lippincott Williams and Wilkins
22. Ebos J.M.L., Lee C.R., Cruz-Munoz W., Bjarnason G.A., Christensen J.G., and Kerbel R.S. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15 3 (2009) 232-239
23. Etoh T., Inoue H., Tanaka S., Barnard G.F., Kitano S., and Mori M. Angiopoietin-2 is related to tumor angiogenesis in gastric carcinoma: possible in vivo regulation via induction of proteases. Cancer Res. 61 5 (2001) 2145-2153
24. Ferrara N. Molecular and biological properties of vascular endothelial growth factor. J. Mol. Med. 77 7 (1999) 527-543
25. Ferrara N. Role of vascular endothelial growth factor in the regulation of angiogenesis. Kidney Int. 56 3 (1999) 794-814
26. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat. Rev. Cancer 2 10 (2002) 795-803
27. Folkman J. What is the evidence that tumors are angiogenesis dependent?. J. Natl. Cancer Inst. 82 1 (1990) 4-6
28. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin. Oncol. 29 6 Suppl. 16 (2002) 15-18
29. Folkman J. Antiangiogenesis in cancer therapy-endostatin and its mechanisms of action. Exp. Cell Res. 312 5 (2006) 594-607
30. Gabhann F.M., and Popel A.S. Differential binding of VEGF isoforms to VEGF receptor 2 in the presence of neuropilin-1: a computational model. Am. J. Physiol. Heart Circ. Physiol. 288 6 (2005) H2851-H2860
31. Gerisch A., and Chaplain M.A.J. Mathematical modelling of cancer cell invasion of tissue: local and non-local models and the effect of adhesion. J. Theor. Biol. 250 4 (2008) 684-704
32. Goldacre R.J., and Sylven B. On the access of blood-borne dyes to various tumour regions. Br. J. Cancer 16 (1962) 306-322
33. Hanahan D., and Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86 3 (1996) 353-364
34. Hogea C.S., Murray B.T., and Sethian J.A. Simulating complex tumor dynamics from avascular to vascular growth using a general level-set method. J. Math. Biol. 53 1 (2006) 86-134
35. Hu B., Guo P., Fang Q., Tao H.-Q., Wang D., Nagane M., Huang H.-J.S., Gunji Y., Nishikawa R., Alitalo K., Cavenee W.K., and Cheng S.-Y. Angiopoietin-2 induces human glioma invasion through the activation of matrix metalloprotease-2. Proc. Natl. Acad. Sci. USA 100 15 (2003) 8904-8909
36. Kevrekidis P.G., Whitaker N., Good D.J., and Herring G.J. Minimal model for tumor angiogenesis. Phys. Rev. E Stat. Nonlin. Soft Matter Phys. 73 6 Pt 1 (2006) 061926
37. Kim Y.-M., Hwang S., Kim Y.-M., Pyun B.-J., Kim T.-Y., Lee S.-T., Gho Y.S., and Kwon Y.-G. Endostatin blocks vascular endothelial growth factor-mediated signaling via direct interaction with kdr/Flk-1. J. Biol. Chem. 277 31 (2002) 27872-27879
38. Koga K., Todaka T., Morioka M., Hamada J., Kai Y., Yano S., Okamura A., Takakura N., Suda T., and Ushio Y. Expression of angiopoietin-2 in human glioma cells and its role for angiogenesis. Cancer Res. 61 16 (2001) 6248-6254
39. Kumar S., and Weaver V.M. Mechanics, malignancy, and metastasis: the force journey of a tumor cell. Cancer Metastasis Rev. 28 1-2 (2009) 113-127
40. Lee D.-S., Rieger H., and Bartha K. Flow correlated percolation during vascular remodeling in growing tumors. Phys. Rev. Lett. 96 5 (2006) 058104
41. Li H.-L., Li S., Shao J.-Y., Lin X.-B., Cao Y., Jiang W.-Q., Liu R.-Y., Zhao P., Zhu X.-F., Zeng M.-S., Guan Z.-Z., and Huang W. Pharmacokinetic and pharmacodynamic study of intratumoral injection of an adenovirus encoding endostatin in patients with advanced tumors. Gene Ther. 15 4 (2008) 247-256
42. Lin X., Huang H., Li S., Li H., Li Y., Cao Y., Zhang D., Xia Y., Guo Y., Huang W., and Jiang W. A phase 1 clinical trial of an adenovirus-mediated endostatin gene (e10a) in patients with solid tumors. Cancer Biol. Ther. 6 5 (2007) 648-653
43. Macklin P., McDougall S., Anderson A.R.A., Chaplain M.A.J., Cristini V., and Lowengrub J. Multiscale modelling and nonlinear simulation of vascular tumour growth. J. Math. Biol. 58 4-5 (2009) 765-798
44. Maisonpierre P.C., Suri C., Jones P.F., Bartunkova S., Wiegand S.J., Radziejewski C., Compton D., McClain J., Aldrich T.H., Papadopoulos N., Daly T.J., Davis S., Sato T.N., and Yancopoulos G.D. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277 5322 (1997) 55-60
45. Mantzaris N.V., Webb S., and Othmer H.G. Mathematical modeling of tumor-induced angiogenesis. J. Math. Biol. 49 2 (2004) 111-187
46. McDougall S.R., Anderson A.R.A., and Chaplain M.A.J. Mathematical modelling of dynamic adaptive tumour-induced angiogenesis: clinical implications and therapeutic targeting strategies. J. Theor. Biol. 241 3 (2006) 564-589
47. Metheny-Barlow L.J., and Li L.Y. The enigmatic role of angiopoietin-1 in tumor angiogenesis. Cell Res. 13 5 (2003) 309-317
48. Moon W.S., Rhyu K.H., Kang M.J., Lee D.G., Yu H.C., Yeum J.H., Koh G.Y., and Tarnawski A.S. Overexpression of VEGF and angiopoietin 2: a key to high vascularity of hepatocellular carcinoma?. Mod. Pathol. 16 6 (2003) 552-557
49. O'Reilly M.S., Boehm T., Shing Y., Fukai N., Vasios G., Lane W.S., Flynn E., Birkhead J.R., Olsen B.R., and Folkman J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88 2 (1997) 277-285
50. Partanen J., Armstrong E., Mäkelä T.P., Korhonen J., Sandberg M., Renkonen R., Knuutila S., Huebner K., and Alitalo K. A novel endothelial cell surface receptor tyrosine kinase with extracellular epidermal growth factor homology domains. Mol. Cell Biol. 12 4 (1992) 1698-1707
51. Paweletz N., and Knierim M. Tumor-related angiogenesis. Crit. Rev. Oncol. Hematol. 9 3 (1989) 197-242
52. Pàez-Ribes M., Allen E., Hudock J., Takeda T., Okuyama H., Viñals F., Inoue M., Bergers G., Hanahan D., and Casanovas O. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15 3 (2009) 220-231
53. Plank M.J., Sleeman B.D., and Jones P.F. A mathematical model of tumour angiogenesis, regulated by vascular endothelial growth factor and the angiopoietins. J. Theor. Biol. 229 4 (2004) 435-454
54. Relf M., LeJeune S., Scott P.A., Fox S., Smith K., Leek R., Moghaddam A., Whitehouse R., Bicknell R., and Harris A.L. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res. 57 5 (1997) 963-969
55. Ribba B., Colin T., and Schnell S. A multiscale mathematical model of cancer, and its use in analyzing irradiation therapies. Theor. Biol. Med. Model. 3 (2006) 7
56. Ribba B., Marron K., Agur Z., Alarcón T., and Maini P.K. A mathematical model of doxorubicin treatment efficacy for non-hodgkin's lymphoma: investigation of the current protocol through theoretical modelling results. Bull Math. Biol. 67 1 (2005) 79-99
57. Ribba B., Saut O., Colin T., Bresch D., Grenier E., and Boissel J.P. A multiscale mathematical model of avascular tumor growth to investigate the therapeutic benefit of anti-invasive agents. J. Theor. Biol. 243 4 (2006) 532-541
58. Ribba B., You B., Tod M., Girard P., Tranchand B., Trillet-Lenoir V., and Freyer G. Chemotherapy may be delivered upon an integrated view of tumor dynamics. IET Syst. Biol 3 (2009) 180-190
59. Sauter B.V., Martinet O., Zhang W.J., Mandeli J., and Woo S.L. Adenovirus-mediated gene transfer of endostatin in vivo results in high level of transgene expression and inhibition of tumor growth and metastases. Proc. Natl. Acad. Sci. USA 97 9 (2000) 4802-4807
60. Sundberg C., Kowanetz M., Brown L.F., Detmar M., and Dvorak H.F. Stable expression of angiopoietin-1 and other markers by cultured pericytes: phenotypic similarities to a subpopulation of cells in maturing vessels during later stages of angiogenesis in vivo. Lab. Invest. 82 4 (2002) 387-401
61. Takahashi G.H., Fatt I., and Goldstick T.K. Oxygen consumption rate of tissue measured by a micropolarographic method. J. Gen. Physiol. 50 2 (1966) 317-335
62. Tanaka F., Ishikawa S., Yanagihara K., Miyahara R., Kawano Y., Li M., Otake Y., and Wada H. Expression of angiopoietins and its clinical significance in non-small cell lung cancer. Cancer Res. 62 23 (2002) 7124-7129
63. Tosin A., Ambrosi D., and Preziosi L. Mechanics and chemotaxis in the morphogenesis of vascular networks. Bull Math. Biol. 68 7 (2006) 1819-1836
64. Welter M., Bartha K., and Rieger H. Emergent vascular network inhomogeneities and resulting blood flow patterns in a growing tumor. J. Theor. Biol. 250 2 (2008) 257-280
65. Zetter B.R. Angiogenesis and tumor metastasis. Annu. Rev. Med. 49 (1998) 407-424
66. Zheng X., Wise S.M., and Cristini V. Nonlinear simulation of tumor necrosis, neo-vascularization and tissue invasion via an adaptive finite-element/level-set method. Bull. Math. Biol. 67 2 (2005) 211-259